Results 171 to 180 of about 50,863 (305)

PeakPASI as a marker of maximum psoriasis severity: a single‐center, cross‐sectional retrospective and questionnaire‐based study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The Psoriasis Area and Severity Index (PASI) is the standard measure for psoriasis severity but reflects only a single time point and may underestimate long‐term disease burden. To assess whether the highest‐ever recorded PASI (PeakPASI) can serve as a marker of historical disease severity and correlate with treatment burden and ...
Simran Wilkhoo, Stefanie Ziehfreund, Enya Müller, Hanna Wecker, Stefanie Eyerich, Tilo Biedermann, Alexander Zink   +6 more
wiley   +1 more source

DAPSA scores reflect both articular and cutaneous involvement in psoriatic arthritis. [PDF]

An Bras Dermatol
Liu Q, Tan M, Kuang Y.
europepmc   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Circulatory microRNA signature distinguishing rheumatoid arthritis and psoriatic arthritis. [PDF]

Rheumatology (Oxford)
Tynan Ó, Hanlon MM, Floudas A, Wade S, Fearon U, Veale DJ.   +5 more
europepmc   +1 more source

Biogenesis of TNF‐α‐insights into proteostasis and inflammation

The FEBS Journal, EarlyView.
TNF‐α biogenesis, trafficking, and signalling are tightly and reciprocally coupled to cellular proteostasis systems, including ER chaperones and endoplasmic reticulum‐associated degradation. This bidirectional crosstalk determines whether TNF‐α responses are adaptive or proteotoxic.
Bailasan Haidar, Céline Philippe, Eric Chevet, Jiří Zahradník   +3 more
wiley   +1 more source

Altered Lipid Metabolism in Psoriatic Arthritis: A Comprehensive Review. [PDF]

Metabolites
Popova-Belova S, Geneva-Popova M, Stoilova S, Popova V, Nikolov G, Nikolov D.   +5 more
europepmc   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, EarlyView.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source

Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies-A Scoping Review. [PDF]

Life (Basel)
Athanassiou L, Kostoglou-Athanassiou I, Kaiafa G, Savopoulos C, Shoenfeld Y, Athanassiou P.   +5 more
europepmc   +1 more source

PDE4 Inhibition in Dermatologic Disease: Impacts Beyond Inflammation

International Journal of Dermatology, EarlyView.
This graphical abstract demonstrates the comprehensive mechanism of PDE4 inhibition in skin physiology. By increasing intracellular cAMP and activating PKA, PDE4 inhibitors exert pleiotropic effects, including immune modulation, pigmentation regulation, barrier enhancement, sensory neuron modulation, and improved wound healing with reduced fibrosis ...
Keana Khodadad, Nicole E. Chin, Raj Chovatiya   +2 more
wiley   +1 more source

Development of IgA nephropathy following risankizumab therapy for psoriatic arthritis: a case report. [PDF]

CEN Case Rep
Yagasaki M, Yamada K, Koshida T, Takagi M, Saeki H, Ogiwara K, Kobayashi T, Kihara M, Gohda T, Suzuki Y.   +9 more
europepmc   +1 more source